Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 27 2023 - 4:15PM
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company
focused on developing its pan-caspase and caspase selective
inhibitors as treatments for infectious and inflammatory diseases
and has a pipeline of restorative therapeutics for orthopedic
indications, today announced the Board of Directors, upon the
recommendation of the Company’s Compensation Committee granted
Alfred J. Spada, the company’s recently appointed Executive Vice
President and Chief Scientific Officer, a nonqualified stock option
to purchase 106,793 shares of Histogen Inc. common stock with an
exercise price of $1.04 based on the closing price on February 23,
2023, the grant date of the award. This grant was made as an
inducement material to Dr. Spada’s acceptance of employment with
Histogen and was approved by the Compensation Committee of
Histogen’s Board of Directors in accordance with Nasdaq Listing
Rule 5635(c)(4).
The non-qualified stock option will vest over a
four-year period, with 25% of the options vesting on the first
anniversary of the employees’ date of hire, and 1/48th of the
options vesting monthly thereafter, subject to the employees’
continued employment with Histogen on such vesting dates and has a
term of ten years.
About Histogen
Histogen Inc. is a clinical-stage therapeutics
company focused on developing potential first-in-class clinical and
preclinical small molecule pan-caspase and caspase selective
inhibitors focused on treatments for infectious and inflammatory
diseases and has a pipeline of restorative therapeutics that ignite
the body’s natural process to repair and maintain healthy
biological function. Under our small molecule pipeline, our product
candidates include emricasan, CTS-2090 and CTS-2096. Currently, we
are evaluating the use of emricasan for bacterial skin infections
including those related to MRSA, as well as other infectious
diseases. We also have preclinical product candidates, CTS-2090 and
CTS-2096, novel, potent, orally bioavailable, and highly selective
small molecule inhibitors of caspase-1 designed for the treatment
of certain inflammatory diseases. Within our biologics technology
platform, our Human Multipotent Cell Conditioned Media, or CCM and
our Human Extracellular Matrix, or hECM are available for
partnering or licensing. For more information, please
visit www.histogen.com.
CONTACT:
Susan A. KnudsonExecutive Vice President &
CFO Histogen Inc. ir@histogen.com
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Apr 2023 to Apr 2024